

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MBX-2982
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the study is to determine if GPR119 agonists have potential to prevent hypoglycemia for people living with T1D. The trial is funded by a nearly $1.2 million grant from The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : MBX-2982
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
